Heterogeneity, urgency, generalizability, and enrollment
The HUGE balance in ALS trials
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Most clinical trials in people with amyotrophic lateral sclerosis (ALS) have not produced successful new drugs.1 Putative new therapies may not work to slow ALS for a number of reasons: perhaps the target is not pertinent or the drug characteristics are unacceptable (e.g., inadequate CNS penetration). If a drug is ineffective in treating ALS, it is best to declare this quickly and move on. If it looks promising, it is best to hasten development. Thus, conducting high-quality, rapid trials is a meaningful goal for ALS trialists. Yet, there are numerous challenges in ALS drug development. Perhaps chief among them is that ALS is a heterogeneous disorder.2 This heterogeneity is most obvious to clinicians and clinical researchers as differences in location of onset, duration of diagnostic delay, and rate of ALS progression.3 This phenotypic heterogeneity can also be threatening: it reduces statistical power, resulting in larger, longer ALS trials. Participant selection criteria are 1 trial design tool that ALS trialists use to try to manage this challenge.
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
See page 222
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.